NKp46 binding proteins

Patent metadata

Field	Value
Publication number	US-11845795-B2
Application number	US-201916677709-A
Country	US
Kind code	B2
Filing date	Nov 8, 2019
Priority date	Jun 27, 2014
Publication date	Dec 19, 2023
Grant date	Dec 19, 2023

Abstract

Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

First claim

The invention claimed is:

1. A method of treating cancer in a subject in need thereof comprising administering to the subject a multispecific protein comprising a first antigen binding domain (ABD) and a second ABD, wherein the first or second ABD[s] binds to a human NKp46 polypeptide and the other binds a cancer antigen expressed by cancer cells of the treated subject,
wherein the first or second ABD binds to human NKp46 polypeptide monovalently, and
wherein the multispecific protein directs an NKp46-expressing NK cell to lyse the cancer cells expressing the cancer antigen; and further wherein:
(a) the first and second ABDs in the multispecific protein comprise variable heavy chain and variable light chain polypeptides, respectively comprising heavy and light chain CDRs specific to human Nkp46 or to the cancer antigen expressed on human cancer cells; and
(b) wherein the first or second ABD in the multispecific protein which binds to a human NKp46 polypeptide is selected from the group consisting of:
(1) a polypeptide comprising a variable heavy chain polypeptide comprising CDR 1, 2 and 3 peptides of the heavy chain variable region of SEQ ID NO: 3 and a variable light chain polypeptide comprising CDR 1, 2 and 3 peptides of the light chain variable region of SEQ ID NO: 4;
(2) a polypeptide comprising a variable heavy chain polypeptide comprising CDR 1, 2 and 3 peptides of the heavy chain variable region of SEQ ID NO: 5 and a variable light chain polypeptide comprising CDR 1, 2 and 3 peptides of the light chain variable region of SEQ ID NO: 6;
(3) a polypeptide comprising a variable heavy chain polypeptide comprising CDR 1, 2 and 3 peptides of the heavy chain variable region of SEQ ID NO: 7 and a variable light chain polypeptide comprising CDR 1, 2 and 3 peptides of the light chain variable region of SEQ ID NO: 8;
(4) a polypeptide comprising a variable heavy chain polypeptide comprising CDR 1, 2 and 3 peptides of the heavy chain variable region of SEQ ID NO: 9 and a variable light chain polypeptide comprising CDR 1, 2 and 3 peptides of the light chain variable region of SEQ ID NO: 10;
(5) a polypeptide comprising a variable heavy chain polypeptide comprising CDR 1, 2 and 3 peptides of the heavy chain variable region of SEQ ID NO: 11 and a variable light chain polypeptide comprising CDR 1, 2 and 3 peptides of the light chain variable region of SEQ ID NO: 12; and
(6) a polypeptide comprising a variable heavy chain polypeptide comprising CDR 1, 2 and 3 peptides of the heavy chain variable region of SEQ ID NO: 13 and a variable light chain polypeptide comprising CDR 1, 2 and 3 peptides of the light chain variable region of SEQ ID NO: 14.

2. The method according to claim 1 , wherein the multispecific protein is administered in combination with a second therapeutic agent, wherein the second therapeutic agent is an antibody that is capable of mediating ADCC toward a cell that expresses an antigen bound by the antibody.

3. The method according to claim 1 , wherein:
(i) said multispecific protein mediates lysis of the target cancer cells expressing the cancer antigen of interest by NKp46-signaling;
(ii) the multispecific protein does not exhibit activation of NKp46-expressing NK cells when incubated with such NK cells in the absence of cells expressing the cancer antigen of interest;
(iii) the multispecific protein does not exhibit activation of NKp46-negative, CD16-positive lymphocytes when incubated with such NK cells in the presence of cancer cells expressing the cancer antigen of interest;
(iv) the multispecific protein (a) activates NK cells, when incubated with NKp46-expressing NK cells and target cancer cells expressing the cancer antigen of interest; and (b) does not activate NKp46-expressing NK cells when incubated with NK cells in the absence of target cancer cells expressing the cancer antigen of interest; and
(v) the multispecific protein does not exhibit activation of NKp46-expressing NK cells when incubated with NK cells and target cancer cells expressing the cancer antigen of interest, in the presence of Fcγ-expressing cells.

4. The method according to claim 1 , wherein the multispecific protein:
(1) is an isolated heterodimeric polypeptide comprising:
(a) a first polypeptide chain comprising, from N- to C-terminus, a first variable domain (V), a CH1 or CK constant region, a Fc domain or CH3 domain thereof, a second variable domain and a third variable domain; and
(b) a second polypeptide chain comprising, from N- to C-terminus, a first variable domain (V), a CH1 or CK constant region, and a Fc domain or CH3 domain thereof, wherein the CH1 or CK constant region is selected to be complementary to the CH1 or CK constant region of the first polypeptide chain such that the first and second polypeptides form a CH1-CK heterodimer in which the first variable domain of the first polypeptide chain and the first variable domain of the second polypeptide form an antigen binding domain that binds human NKp46; and wherein a second variable domain and third variable domain forms an antigen binding domain that binds the cancer antigen; or

(2) is an isolated heterodimeric polypeptide comprising:
(a) a first polypeptide having a domain arrangement selected from:
Va-1-(CH1 or CK)a-Fc domain-Va-2-Vb-2, and
Va-2-Vb-2-Fc domain-Va-1-(CH1 or CK)b,
and
(b) a second polypeptide chain having a domain arrangement:
Vb-1-(CH1 or CK)b, and
wherein one of Va-1 and Vb-1 is a light chain variable domain and the other is a heavy chain variable domain, and one of Va-2 and Vb-2 is a light chain variable domain and the other is a heavy chain variable domain;
wherein (CH1 or CK)b dimerizes with the (CH1 or CK)a on the central chain, and the Vb-1 forms a first antigen binding domain together with Va-1 of the central chain, and wherein Va-2 and Vb-2 together form a second antigen binding domain, wherein either the first or the second antigen binding domain binds to human NKp46, and the other binds to the cancer antigen; or

(3) is an isolated heterodimeric polypeptide comprising:
a first polypeptide having a domain arrangement:
V a-1 -(CH1 or CK) a -Fc domain-V a-2 -V b-2 ,
and
(b) a second polypeptide chain having a domain arrangement:
V b-1 -(CH1 or CK) b -Fc domain
wherein one of Va-1 and Vb-1 is a light chain variable domain and the other is a heavy chain variable domain, one of Va-2 and Vb-2 is a light chain variable domain and the other is a heavy chain variable domain; said (CH1 or CK)b dimerizes with the (CH1 or CK)a on the central chain, and the Vb-1 forms a first antigen binding domain together with Va-1 of the central chain; and Va-2 and Vb-2 together form a second antigen binding domain, wherein either the first or the second antigen binding domain binds to human NKp46, and the other binds to the cancer antigen.

5. The method according to claim 4 , wherein in said multispecific protein Va-2 and Vb-2 together form an antigen binding domain that binds NKp46.

6. The method according to claim 1 , wherein the multispecific protein:
(1) is an isolated heterotrimeric polypeptide comprising
(a) a first polypeptide chain comprising, from N- to C-terminus, a first variable domain (V) fused to a first CH1 or CK constant region, an Fc domain or CH3 domain thereof, and a second variable domain (V) fused to a second CH1 or CK constant region;
(b) a second polypeptide chain comprising, from N- to C-terminus, a third variable domain (V) fused to a CH1 or CK constant region selected to be complementary to the first (but not the second) CH1 or CK constant region of the first polypeptide chain such that the first and second polypeptides form a CH1-CK heterodimer, and an Fc domain or CH3 domain thereof; and
(c) a third polypeptide chain comprising, from N- to C-terminus, a fourth variable doma

Assignees

• Innate Pharma

Inventors

• Gauthier Laurent
• Anceriz Nadia
• Morel Ariane
• Rossi Benjamin

Classifications

• C07K16/2803 Primary

  against the immunoglobulin superfamily · CPC title

• C07K16/2866

  against receptors for cytokines, lymphokines, interferons · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title